SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Premature birth needs to be in specialist centres - study
Thurs October 17th - Women facing premature labour should be enabled to give birth in hospitals with specialist neonatal intensive care units, researchers say today. More
How GPs can respond to private gene test results
Thurs October 17th - Doctors confronted by patients armed with the results of private gene testing should check for family genetic history that might support the claimed results, according to experts today. More
RECENT COMMENTS
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
On 12/03/2017 Steph wrote:
The photo you have paired with this article is its... on 'Fat shaming' limits...
ASTHMA & ALLERGY BOOKS
Clearing the air: An Assessment of Asthma and Indoor Allergens ABC of Asthma For more books click here
ALLERGY NEWS
ALLERGY RSS FEEDS
RSS graphic XML Graphic
ENGLEMED HEALTH NEWS

Backing for asthma triple therapy inhaler

Tuesday October 1st, 2019

A triple therapy inhaler may be the best way to help patients with severe and uncontrolled asthma, according to the findings of a major international study.

One triple therapy reduced the number of severe asthma attacks by 15%, according to the findings of the studies conducted over 17 countries.

The findings were reported to the conference of the European Respiratory Society in Madrid, Spain, yesterday and also published in The Lancet.

Researchers ran two trials and the most successful, Trimaran, combined a medium strength dose of corticosteroid, a long-acting beta agonist and a muscarinic antagonist in a single inhaler dose - and involved some 579 patients.

The European study found that triple therapy enabled patients to exhale significantly more air compared with a double therapy.

The Trimaran trial also found the 15% reduction in moderate and severe attack.

Researcher Professor Christian Virchow, from the Rostock University Medical Centre, Germany, said: "The patients in our studies had been using preventer inhalers combining two medicines but they weren't working as effectively as they do for most asthma sufferers. The effects of triple therapy might seem moderate when you look at the numbers involved, but even incremental improvements can be valuable when there are few treatment options left available."

Fellow researcher Sandrine Corre, from Chiesi Farmaceutici, Italy, funder of the trial, said: "Since the preventive treatment we trialled delivers three drugs via one inhaler, and given the reduction we saw in the annual rate of severe asthma attacks, we expect it will provide an attractive option helping to fulfil an unmet need for both individuals and health systems."

Lancet 30 September 2019

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32215-9/fulltext

Tags: Allergies & Asthma | Europe | Pharmaceuticals

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES